Nanomedicine Against Aβ Aggregation by β-Sheet Breaker Peptide Delivery: In Vitro Evidence.
Alzheimer disease (AD)
Aβ
KLVFF peptide
Polymeric nanoparticles (NPs)
amyloid β
blood-brain barrier (BBB)
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
01 Nov 2019
01 Nov 2019
Historique:
received:
08
10
2019
revised:
24
10
2019
accepted:
30
10
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
The accumulation of amyloid β (Aβ) triggers a cascade of toxic events in Alzheimer's disease (AD). The KLVFF peptide can interfere with Aβ aggregation. However, the peptide suffers from poor bioavailability and the inability to cross the blood-brain barrier. In this work, we study the possibility of adopting nanomedicine to overcome KLVFF limits in biodistribution. We produced new engineered polymeric nanoparticles (NPs), and we evaluated the cellular toxicity of these NPs and validated that KVLFF peptides released by NPs show the same promising effects on AD pathology. Our results revealed the successful generation of KVLFF loaded NPs that, without significant effects on cell heath, are even more potent in reversing Aβ-induced pathologies compared to the free peptide. Therefore, NPs will significantly advance KVLFF treatment as a therapeutic option for AD.
Identifiants
pubmed: 31683907
pii: pharmaceutics11110572
doi: 10.3390/pharmaceutics11110572
pmc: PMC6920811
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : UNIMORE
ID : Grant FAR 2016
Organisme : MEACI grant
ID : Nanomedicine for BBB-crossing in CNS oncologic pathologies
Organisme : Evangelisches Studienwerk Villigst e.V.
ID : PhD fellowship
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
PLoS One. 2016 May 26;11(5):e0156452
pubmed: 27228099
J Biol Chem. 1996 Nov 22;271(47):29525-8
pubmed: 8939877
Curr Pharm Des. 2012;18(6):755-67
pubmed: 22236121
Bioconjug Chem. 2003 Jan-Feb;14(1):86-92
pubmed: 12526697
Mol Med Rep. 2018 Jul;18(1):639-655
pubmed: 29845262
EMBO Mol Med. 2015 Nov 20;7(12):1547-64
pubmed: 26589247
ACS Chem Neurosci. 2010 Oct 20;1(10):661-78
pubmed: 22778807
Nanomedicine. 2011 Oct;7(5):521-40
pubmed: 21477665
Front Neurosci. 2015 Nov 04;9:423
pubmed: 26582973
J Control Release. 2012 Jul 20;161(2):505-22
pubmed: 22353619
Chem Commun (Camb). 2017 Jan 19;53(7):1289-1292
pubmed: 28067349
Nat Commun. 2018 May 4;9(1):1802
pubmed: 29728565
Biochemistry. 2001 Jul 27;40(28):8237-45
pubmed: 11444969
Nanomedicine (Lond). 2013 Sep;8(9):1373-83
pubmed: 23565661
Neuron. 2014 May 21;82(4):756-71
pubmed: 24853936
Mol Neurodegener. 2011 Sep 22;6:65
pubmed: 21939532
Cell Mol Life Sci. 2014 Sep;71(18):3507-21
pubmed: 24803005
J Control Release. 2014 Jan 28;174:195-201
pubmed: 24316476
J Pept Res. 2001 Oct;58(4):342-6
pubmed: 11606220
J Trace Elem Med Biol. 2018 Sep;49:210-221
pubmed: 29325805
J Phys Chem B. 2011 Jun 9;115(22):7433-46
pubmed: 21563780
Biophys J. 1999 Mar;76(3):1330-4
pubmed: 10049316
Int J Mol Sci. 2019 Apr 24;20(8):null
pubmed: 31022913
Nano Lett. 2019 Feb 13;19(2):674-683
pubmed: 30444372
Int J Pharm. 2015 Jul 25;490(1-2):85-93
pubmed: 25987470
Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7612-6
pubmed: 9207140
Nat Med. 1998 Jul;4(7):822-6
pubmed: 9662374
J Alzheimers Dis. 2012;29(1):159-70
pubmed: 22232005
Nat Rev Drug Discov. 2011 Aug 19;10(9):698-712
pubmed: 21852788
Biochem Biophys Res Commun. 1996 Sep 24;226(3):672-80
pubmed: 8831674
J Am Chem Soc. 2017 Mar 29;139(12):4298-4301
pubmed: 28290684
J Biol Chem. 1996 Apr 12;271(15):8545-8
pubmed: 8621479